GovBidAlerts
OpenPresolicitationFederal

Preclinical Medications Discovery and Abuse Liability Testing for NIDA

Department of Health and Human Services · National Institutes of Health

Due Closes in 9 daysRef. 75N95022C00004

At a glance

What

NOTICE OF A PROPOSED CONTRACT ACTION NON-COMPETITIVE Notice ID: 75N95022C00004 Contract Opportunity Type: Presolicitation Response Date: November 27, 2026, at 1:00 PM Eastern Time (15 days) Classification: No Small Business Set Aside Used…

Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715)

Who can bid
Any business — no set-aside listed
Where
Bethesda, MD
Key dates
  • Posted: Nov 13, 2026
  • Deadline: Fri, Nov 27, 2026 · 1:00 PM EST (closes in 9 days)
How to respond

shayna simpson · shayna.simpson@nih.gov

Submit per the instructions on SAM.gov ↗

Documents
None attached here — check SAM.gov

Description

NOTICE OF A PROPOSED CONTRACT ACTION NON-COMPETITIVE Notice ID: 75N95022C00004 Contract Opportunity Type: Presolicitation Response Date: November 27, 2026, at 1:00 PM Eastern Time (15 days) Classification: No Small Business Set Aside Used Product Service Code: AN11 NAICS Code: 541715 Place of Performance: Blank Description PURSUANT TO RFO 5.101 — PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION. THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022C00004 WITH VIRGINIA COMMONWEALTH UNIVERSITY. THIS IS NOT A SOLICITATION OR A REQUEST FOR COMPETITIVE PROPOSALS. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), through the Addiction Treatment Discovery Program (ATDP) within NIDA’s Division of Therapeutics and Medical Consequences (DTMC), intends to modify Single Award Contract No.
Read more ↓
75N95022C00004, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA,” to extend the period of performance by 12-months through February 21, 2027. All other terms and conditions remain unchanged. This modification will allow for the continuation of ongoing research conducted under the Preclinical Medications Discovery and Abuse Liability Testing program for NIDA and prevent any delays or disruption to the development of therapeutics essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. REGULATORY AUTHORITY The resultant modification will include all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26. STATUTORY AUTHORITY This modification is conducted under the authority of 41 U.S.C. 3304(a)(1) and in accordance with RFO 6.103-1 Only one responsible source and no other supplies or services will satisfy agency requirements. CLOSING STATEMENT THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by the closing date and time of this announcement and must reference the Project Title, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA.” Responses must be submitted electronically to Shayna Simpson, Contracting Officer, at shayna.simpson@nih.gov. Mailed and faxed responses will not be accepted. PRIMARY POINT OF CONTACT: Shayna Simpson Email: shayna.simpson@nih.gov Phone: 301-402-9712
All notice detailsShow ↓
Solicitation number
75N95022C00004
Notice type
Presolicitation
Product/service code (PSC)
AN11
Department
Department of Health and Human Services
Sub-agency
National Institutes of Health
Contracting office
NATIONAL INSTITUTES OF HEALTH OLAO
Office location
BETHESDA, MD, 20892
Place of performance
Bethesda, Maryland, UNITED STATES
Archive date
Dec 12, 2026
Archive type
auto15
Office code
075.7529.75N980
Organization type
OFFICE
Full agency path
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.NATIONAL INSTITUTES OF HEALTH.NATIONAL INSTITUTES OF HEALTH OLAO
SAM.gov notice ID
54f02db654c1489dadd4275bbb1462d9

Contacts